← Leaderboards

Steven P. Balk

Dana-Farber Cancer Inst

Google Scholar ↗PubMed ↗ORCID ↗

$19,509,335

Attributed

$22,290,613

Total exposure

24

Grants

20

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.2M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$55,658,264 · 27

By mechanism

P01$24,479,815 · 7

P50$15,330,238 · 4

R01$12,840,538 · 8

T32$1,466,449 · 1

P30$545,237 · 3

R21$518,500 · 2

Top collaborators

Most similar at Dana-Farber Cancer Inst

Same institution · by research overlap

Lorelei Mucci$13,743,245
Kexin Xu$3,572,606
David Yoshio Takeda$531,168

Others in their field

Top investigators on “Androgen Receptor”

Susan E. Hankinson · University Of Massachusetts Amherst$24,278,267
Diane E Merry · Thomas Jefferson University$17,810,180
Charles L Sawyers · Sloan-Kettering Inst Can Research$17,232,913
Richard D Schulick · Johns Hopkins University$17,086,121
Shalendar Bhasin · La Biomed Res Inst/ Harbor Ucla Med Ctr$16,194,198
Xiaoqi Liu · Harvard University$15,300,481

Research focus

Androgen ReceptorMalignant Neoplasm Of ProstateAndrogensSamplingClinical TrialsResistanceMolecularResistance MechanismTumorBaseMediatingAbirateroneProgramsCastration Resistant Prostate CancerResponseRelapseCastrationFundingTranslatingAutomobile DrivingCellsResearch PersonnelCancer PatientPathway Interactions

Grant awards (106)

DF/HCC Prostate SPORE$2,079,312

P50 · FY2025 · CA

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,990,456

P01 · FY2025 · CA · contact PI

Enhancing the Efficacy of Docetaxel in Prostate Cancer$654,537

R01 · FY2025 · CA · contact PI

Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs$400,313

R01 · FY2025 · CA · contact PI

WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer$395,509

R01 · FY2025 · CA · contact PI

Administrative Core$331,744

P01 · FY2025 · CA · contact PI

Identify Mechanisms Driving Resistance to AR Antagonists in CRPC$331,743

P01 · FY2025 · CA · contact PI

Program 03 Prostate Cancer$59,487

P30 · FY2025 · CA · contact PI

DF/HCC Prostate SPORE$2,393,890

P50 · FY2024 · CA

Enhancing the Efficacy of Docetaxel in Prostate Cancer$621,810

R01 · FY2024 · CA · contact PI

Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs$380,298

R01 · FY2024 · CA · contact PI

WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer$375,734

R01 · FY2024 · CA · contact PI

Program 03 Prostate Cancer$40,622

P30 · FY2024 · CA · contact PI

DF/HCC Prostate SPORE$2,585,567

P50 · FY2023 · CA

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,431,923

P01 · FY2023 · CA · contact PI

Enhancing the Efficacy of Docetaxel in Prostate Cancer$641,446

R01 · FY2023 · CA · contact PI

WNT5a/ROR2-Mediated Hippo Pathway Activation in Prostate Cancer$395,509

R01 · FY2023 · CA · contact PI

Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs$392,306

R01 · FY2023 · CA · contact PI

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance$237,526

P01 · FY2023 · CA · contact PI

Targeting androgen receptor signaling in prostate cancer in men with African ancestry$171,500

U54 · FY2023 · CA · contact PI

Core A: Administrative Core$88,202

P01 · FY2023 · CA · contact PI

Program 03 Prostate Cancer$41,764

P30 · FY2023 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,429,408

P01 · FY2022 · CA · contact PI

Enhancing the Efficacy of Docetaxel in Prostate Cancer$672,762

R01 · FY2022 · CA · contact PI

Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs$392,306

R01 · FY2022 · CA · contact PI

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance$237,351

P01 · FY2022 · CA · contact PI

Targeting androgen receptor signaling in prostate cancer in men with African ancestry$96,302

U54 · FY2022 · CA · contact PI

Core A: Administrative Core$86,561

P01 · FY2022 · CA · contact PI

Program 03 Prostate Cancer$41,764

P30 · FY2022 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,458,578

P01 · FY2021 · CA · contact PI

Prostate Cancer Vulnerabilities to BH3 Mimetic Drugs$400,313

R01 · FY2021 · CA · contact PI

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance$365,099

P01 · FY2021 · CA · contact PI

Targeting androgen receptor signaling in prostate cancer in men with African ancestry$209,685

U54 · FY2021 · CA · contact PI

Core A: Administrative Core$88,383

P01 · FY2021 · CA · contact PI

Program 3: Prostate Cancer$71,570

P30 · FY2021 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,464,494

P01 · FY2020 · CA · contact PI

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance$365,099

P01 · FY2020 · CA · contact PI

Core A: Administrative Core$94,299

P01 · FY2020 · CA · contact PI

Program 3: Prostate Cancer$71,457

P30 · FY2020 · CA · contact PI

Program 3: Prostate Cancer$2,949

P30 · FY2020 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$1,546,415

P01 · FY2019 · CA · contact PI

Project 2: Mechanisms Driving AR Full Length and Splice Variant Activities and Antagonist Resistance$365,103

P01 · FY2019 · CA · contact PI

Core A: Administrative Core$101,218

P01 · FY2019 · CA · contact PI

Program 3: Prostate Cancer$69,826

P30 · FY2019 · CA · contact PI

Program 3: Prostate Cancer$6,168

P30 · FY2019 · CA · contact PI

SOX9 Mediation of AR and ERG Driven Prostate Cancer$361,050

R01 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$71,488

P30 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$11,431

P30 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$5,849

P30 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$5,123

P30 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$3,833

P30 · FY2018 · CA · contact PI

Program 3: Prostate Cancer$1,602

P30 · FY2018 · CA · contact PI

DF/HCC SPORE in Prostate Cancer$2,300,000

P50 · FY2017 · CA

Androgen Receptor Action in Castration Resistant Prostate Cancer$2,045,478

P01 · FY2017 · CA · contact PI

Targeting Mechanisms Driveing AR Activity in Advanced CRPC$378,750

P50 · FY2017 · CA · contact PI

SOX9 Mediation of AR and ERG Driven Prostate Cancer$361,050

R01 · FY2017 · CA · contact PI

Basis for Androgen Receptor Antagonist Resistance in CRPC$293,118

P01 · FY2017 · CA · contact PI

Administrative/Clinical/Biostatistics Core$137,494

P01 · FY2017 · CA · contact PI

Program 3: Prostate Cancer$40,304

P30 · FY2017 · CA · contact PI

DF/HCC SPORE in Prostate Cancer$2,162,000

P50 · FY2016 · CA

Androgen Receptor Action in Castration Resistant Prostate Cancer$2,045,071

P01 · FY2016 · CA · contact PI

SOX9 Mediation of AR and ERG Driven Prostate Cancer$361,050

R01 · FY2016 · CA · contact PI

Targeting Mechanisms Driveing AR Activity in Advanced CRPC$308,708

P50 · FY2016 · CA · contact PI

Basis for Androgen Receptor Antagonist Resistance in CRPC$293,055

P01 · FY2016 · CA · contact PI

Administrative/Clinical/Biostatistics Core$137,547

P01 · FY2016 · CA · contact PI

DF/HCC SPORE in Prostate Cancer$2,185,000

P50 · FY2015 · CA

Androgen Receptor Action in Castration Resistant Prostate Cancer$2,055,706

P01 · FY2015 · CA · contact PI

SOX9 Mediation of AR and ERG Driven Prostate Cancer$361,050

R01 · FY2015 · CA · contact PI

Targeting Mechanisms Driveing AR Activity in Advanced CRPC$306,360

P50 · FY2015 · CA · contact PI

Basis for Androgen Receptor Antagonist Resistance in CRPC$262,988

P01 · FY2015 · CA · contact PI

Administrative/Clinical/Biostatistics Core$150,317

P01 · FY2015 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$2,010,837

P01 · FY2014 · CA · contact PI

SOX9 Mediation of AR and ERG Driven Prostate Cancer$361,050

R01 · FY2014 · CA · contact PI

Targeting Mechanisms Driveing AR Activity in Advanced CRPC$336,867

P50 · FY2014 · CA · contact PI

Basis for Androgen Receptor Antagonist Resistance in CRPC$283,515

P01 · FY2014 · CA · contact PI

Administrative/Clinical/Biostatistics Core$133,318

P01 · FY2014 · CA · contact PI

Androgen Receptor Action in Castration Resistant Prostate Cancer$2,183,516

P01 · FY2013 · CA · contact PI

Targeting Mechanisms Driveing AR Activity in Advanced CRPC$293,784

P50 · FY2013 · CA · contact PI

Basis for Androgen Receptor Antagonist Resistance in CRPC$292,751

P01 · FY2013 · CA · contact PI

Administrative/Clinical/Biostatistics Core$141,502

P01 · FY2013 · CA · contact PI

Training Grant in Cancer Biology$315,980

T32 · FY2011 · CA · contact PI

Targeting AR-NCoR Interaction in Prostate Cancer$313,310

R01 · FY2011 · CA · contact PI

Targeting AR-NCoR Interaction in Prostate Cancer$323,000

R01 · FY2010 · CA · contact PI

Training Grant in Cancer Biology$230,248

T32 · FY2010 · CA · contact PI

Training Grant in Cancer Biology$338,951

T32 · FY2009 · CA · contact PI

Targeting AR-NCoR Interaction in Prostate Cancer$323,000

R01 · FY2009 · CA · contact PI

Training Grant in Cancer Biology$50,815

T32 · FY2009 · CA · contact PI

Targeting AR-NCoR Interaction in Prostate Cancer$323,000

R01 · FY2008 · CA · contact PI

Training Grant in Cancer Biology$263,407

T32 · FY2008 · CA · contact PI

Targeting AR-NCoR Interaction in Prostate Cancer$323,000

R01 · FY2007 · CA · contact PI

Training Grant in Cancer Biology$267,048

T32 · FY2007 · CA · contact PI

AR Transgene Model of Prostate Intraepithelial Neoplasia$385,444

R01 · FY2006 · DK · contact PI

HTS for Androgen Receptor Antagonists that Recruit NCoR$212,500

R21 · FY2006 · NS · contact PI

AR Transgene Model of Prostate Intraepithelial Neoplasia$394,720

R01 · FY2005 · DK

AR Transgene Model of Prostate Intraepithelial Neoplasia$394,720

R01 · FY2004 · DK

AR Transgene Model of Prostate Intraepithelial Neoplasia$394,720

R01 · FY2003 · DK

IMMUNE REGULATION BY CD1D REACTIVE NKR-P1 T CELLS$272,075

R01 · FY2003 · AI

AR Transgene Model of Prostate Intraepithelial Neoplasia$418,625

R01 · FY2002 · DK

IMMUNE REGULATION BY CD1D REACTIVE NKR-P1 T CELLS$264,151

R01 · FY2002 · AI

Invariant NKT Cells For Phase 1 Cancer Trials$153,000

R21 · FY2002 · CA

Androgen receptor in hormone refractory disease$0

P50 · FY2002 · CA

FUNCTION OF HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES$343,622

R01 · FY2001 · AI

IMMUNE REGULATION BY CD1D REACTIVE NKR-P1 T CELLS$256,459

R01 · FY2001 · AI

Invariant NKT Cells For Phase 1 Cancer Trials$153,000

R21 · FY2001 · CA

FUNCTION OF HUMAN INTESTINAL INTRAEPITHELIAL LYMPHOCYTES$333,614

R01 · FY2000 · AI

IMMUNE REGULATION BY CD1D REACTIVE NKR-P1 T CELLS$248,985

R01 · FY2000 · AI